MedEdTalks - Ophthalmology

In this podcast, expert faculty review the therapeutic landscape of vitreoretinal care and discuss the latest from Clinical Trials at the Summit 2026. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://vindicocme.com/mededtalks/1the-retina-radar-season-4-with-dr-arshad-khanani-clinical-trials-at-the-summit-2026-with-drs-david-boyer-and-anat-loewenstein-blt810e98f995192db2/overview

In this podcast, expert faculty discuss durability-focused treatment strategies and long-term clinical data to optimize outcomes for patients with nAMD. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://vindicocme.com/mededtalks/2the-retina-radar-season-4-with-dr-arshad-khanani-latest-in-namd-management-in-2026-with-dr-yasha-modi-bltbc205cf637dc6313/overview

In this podcast, expert faculty discuss the latest clinical trial data and real-world studies on approved and emerging therapies for DME. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://vindicocme.com/mededtalks/3the-retina-radar-season-4-with-dr-arshad-khanani-latest-in-dme-management-in-2026-with-dr-margaret-chang-blt0238f9ad223ce3d2/overview

In this podcast, expert faculty discuss current treatment strategies and emerging clinical data to optimize outcomes for patients with RVO.   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://vindicocme.com/mededtalks/4the-retina-radar-season-4-with-dr-arshad-khanani-what-s-new-for-rvo-in-2026-with-dr-ehsan-rahimy-blt18909863eb2c3acd/overview

The treatment landscape for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) continues to evolve, with ongoing efforts to improve durability and reduce treatment burden. Longer-acting second-generation anti-VEGF therapies, including aflibercept 8 mg and faricimab, have demonstrated the potential to extend dosing intervals while maintaining improved visual and anatomic outcomes across these retinal diseases. Emerging real-world and extension-study data are further informing the long-term safety, efficacy, and clinical application of these therapies. However, adherence barriers, undertreatment, safety considerations, access disparities, and uncertainty regarding patient selection continue to present challenges in achieving optimal outcomes. Clinicians must also understand differences in clinical trial design to critically interpret emerging evidence and apply durability data into individualized patient care. In this Rapid Response CE activity, experts in the field review abstracts presented at EURETINA, Retina Society, and The American Academy of Ophthalmology and discuss recent clinical evidence on approved second-generation anti-VEGF therapies to support evidence-based management of treatment naïve and previously treated patients with retinal diseases.   To claim CME credit, please visit HealioCME.com and search for this activity title

This podcast series delves into the evidence for oral micronutrient therapy in slowing the progression of age-related macular degeneration (AMD). In this episode, experts in the field discuss potential implications of expanded formulations of AMD supplements and interprofessional approaches for counseling patients. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20260828/3whats-next-for-nutritional-strategies-in-amd-care

This podcast series delves into the evidence for oral micronutrient therapy in slowing the progression of age-related macular degeneration (AMD). In this episode, experts in the field discuss the emerging evidence for incorporation of B vitamins into AMD supplementation and implications for evolving oral micronutrient strategies. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20260828/2emerging-evidence-on-b-vitamins-and-expanded-nutritional-strategies-in-amd

This podcast series delves into the evidence for oral micronutrient therapy in slowing the progression of age-related macular degeneration (AMD). In this episode, experts in the field discuss the evidence base for AMD-specific supplementation and key considerations for incorporating oral micronutrient therapy into AMD management.   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20260828/1current-evidence-for-oral-micronutrient-therapy-in-amd

The treatment landscape for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) continues to evolve, with ongoing efforts to improve durability and reduce treatment burden. Longer-acting second-generation anti-VEGF therapies, including aflibercept 8 mg and faricimab, have demonstrated the potential to extend dosing intervals while maintaining improved visual and anatomic outcomes across these retinal diseases. Emerging real-world and extension-study data are further informing the long-term safety, efficacy, and clinical application of these therapies. However, adherence barriers, undertreatment, safety considerations, access disparities, and uncertainty regarding patient selection continue to present challenges in achieving optimal outcomes. Clinicians must also understand differences in clinical trial design to critically interpret emerging evidence and apply durability data into individualized patient care. In this Rapid Response CE activity, experts in the field review abstracts presented at The American Society of Retina Specialists and discuss recent clinical evidence on approved second-generation anti-VEGF therapies to support evidence-based management of treatment naïve and previously treated patients with retinal diseases. To claim CME credit, please visit HealioCME.com and search for this activity title

Second-generation anti-vascular endothelial growth factor (VEGF) therapies approved for the management of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) continue to be evaluated in ongoing clinical and real-world studies. Findings from these studies provide additional insights to guide the incorporation of these therapies into clinical practice, with the goal of enhancing visual and anatomic outcomes while reducing treatment burden in patients with retinal diseases. Although keeping up to date with emerging data can be challenging, doing so is essential for the optimal integration of second-generation anti-VEGF therapies into patient care. In this CE activity, experts in the field evaluate recent clinical evidence on approved second-generation anti-VEGF therapies to inform the management of treatment naive and previously treated patients with retinal diseases.   To claim CME credit, please visit HealioCME.com and search for this activity title